Evusheld (tixagevimab;cilgavimab)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- tixagevimab;cilgavimab
- Company
- AstraZeneca AB
- Status
- Withdrawn
- Therapeutic area
- COVID-19 virus infection
- CHMP opinion
- Thu 24 Mar 2022
- EU approval
- Fri 25 Mar 2022
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005788
- Official record
- www.ema.europa.eu
Indication
Prevention of COVID-19.
Regulatory milestones
No milestones recorded in the last year.
Follow Evusheld
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.